Aquestive Therapeutics, Inc. announced the election of Richard J. Daly to its Board of Directors, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meeting of Stockholders. The appointment was recommended by the Company’s Nominating and Corporate Governance Committee following a formal search conducted with the assistance of an independent executive search firm.
The Board has determined that Mr. Daly is an independent director under applicable Nasdaq listing standards. He brings more than 30 years of experience in the life sciences sector, including senior commercial and operating roles at AstraZeneca, Takeda, and Catalyst Pharmaceuticals. Mr. Daly currently serves as President of Global Rare Disease at Angelini Pharma S.p.A. following its acquisition of Catalyst Pharmaceuticals, where he previously served as President and Chief Executive Officer.
In connection with the appointment, the Board approved an increase in the total number of directors from seven to eight. Following the election, the Board will consist of eight directors, seven of whom are independent. Mr. Daly will participate in the Company’s non-employee director compensation program and will be granted an initial award of 57,000 stock options under the Company’s 2018 Equity Incentive Plan. The options will vest in annual one-third increments starting one year after the grant date and will have an exercise price equal to the closing market price on the grant date.
